Subclinical Hepatocellular Carcinoma

  • Tang Zhao-You
  • Yu Ye-Qin
  • Yang Bing-Hui


Ten years ago, 3254 cases with primary liver cancer (PLC) in China were analyzed. The extremely high proportion of late stage patients with jaundice or ascites (52.6%), the extremely low series resection rate (5.3%), and the dismal ultimate outcome (1-year survival, 8.6%) revealed that PLC was indeed an enormous malignancy [23]. Every year, PLC causes 250 000 deaths in the world [29], 100 000 deaths in China [9], and 3000 deaths in Shanghai [3]. However, encouraging things have happened in China recently:
  1. 1.

    Hepatitis B virus (HBV), aflatoxin, contamination of drinking water, and other chemicals are considered to be etiological factors; identification of the transforming gene N-ras in PLC has been reported.

  2. 2.

    The concept of subclinical hepatocellular carcinoma (SCHCC) has been developed on the basis of alpha fetoprotein (AFP) serosurvey, involving a new approach to early detection, revision of the principles underlying surgical treatment, new insight into the natural history of hepatocellular carcinoma (HCC), and renewal of the prognostic concept, particularly with 5-year survival after resection of SCHCC up to 72.9% [19, 26].

  3. 3.

    Multimodality and aggressive approaches to the treatment of symptomatic PLC.

  4. 4.

    Establishment of human HCC cell lines and transplantable human HCC in immune-deficient animals.

  5. 5.

    More concern has been centered on the study of HCC cell membrane and its glycoprotein, glycolipid components in basic research.

  6. 6.

    Radioimmunodetection and radioimmunotherapy by using appropriate antibodies is also under way.



Primary Liver Cancer Alpha Fetoprotein Prognostic Pattern Subclinical Recurrence Therapeutic Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Axtell IM, Cutler SJ, Myers MH: End results in Cancer. Report No. 4, pp. 72–76, US Department of Health, Education and Welfare, Public Health Service, NIH, NCI, Bethesda, MD 1972Google Scholar
  2. 2.
    Curutchet HP, Terz JJ, Kay S et al.: Primary liver cancer. Surgery 70 (1971) 467–479PubMedGoogle Scholar
  3. 3.
    Dept. Epidemiology of Shanghai Cancer Institute, Shanghai Sanitary-antiepidemic Center: Analysis of cancer incidence, mortality and survival rates in Shanghai urban area during the period 1972–79. Tumor 2 (1982) 385. (In Chinese)Google Scholar
  4. 4.
    Ervasti J: Primary carcinoma of the liver — a pathologic and clinical study of 100 cases. Acta chir. scand. 334 (1964) 1s–65s.Google Scholar
  5. 5.
    Gao RN, Tu JT, Gao YT: A preliminary report of etiological and epidemiological studies on primary liver cancer in Chongming County of Shanghai. Tumor 1 (1981) 148–151. (In Chinese)Google Scholar
  6. 6.
    Gustafson EG: An analysis of 62 cases of primary carcinoma of the liver based on 24,000 necropsies at Bellevue Hospital. Ann. intern. Med. 11 (1937) 889–900Google Scholar
  7. 7.
    Heyward WL, Lanier AP, Bender TR et al.: Early detection of primary hepatocellular carcinoma by screening for alpha-fetoprotein in high-risk families — a case report. Lancet 1983, 11: 1161–1162CrossRefGoogle Scholar
  8. 8.
    Hong JX, Zhang QJ, Liu LW et al.: Study on the function of normal human B lymphocytes in the culture with aflatoxin B1. In 1984 Tumor Scientific Reports Abstract, p. 21. Shanghai Cancer Institute, WHO Collaborating Centre for Research on Cancer, 1985Google Scholar
  9. 9.
    LiB, Li JY: National survey of cancer mortality in China. Chin. J. Oncol. 2 (1980) 1–10. (in Chinese)Google Scholar
  10. 10.
    Lin TZ, Zhang QJ, Len YW et al.: Study on immunological mechanism of carcinogenesis of primary liver cancer. In 1984 Tumor Scientific Reports Abstract, p. 33. Shanghai Cancer Institute, WHO Collaborating Centre for Research on Cancer, 1985Google Scholar
  11. 11.
    Liu YX, YuXS, Gao RN et al.: Association of HLA antigen and HCC. Cancer Res. Prev. Treatm. 11 (1984) 65–67. (in Chinese)Google Scholar
  12. 12.
    Liu YX, Yu XS, Yang YQ et al.: In vitro effect of aflatoxin B1 on human peripheral blood lymphocytes. Tumor 1 (1981) 249–250. (In Chinese)Google Scholar
  13. 13.
    Lu HM, Chen J, Jiang KL et al.: The value of serum 5′-nucleotide phosphodiesterase isozyme in the diagnosis of primary liver cancer. Nat. med. J. China 61 (1981) 219–221. (In Chinese)Google Scholar
  14. 14.
    Okuda K, The Liver Cancer Study Group of Japan: Primary liver cancers in Japan. Cancer 45 (1980)2663–2669CrossRefGoogle Scholar
  15. 15.
    Rosenberg DML, OshsnerA: Primary carcinoma of the liver — an analysis of fifty five autopsied cases, the record of a case with resection, and a review of the recent literature. Surgery 24 (1948) 1036–1068PubMedGoogle Scholar
  16. 16.
    Shanghai Coordinating Group for Research on Liver Cancer: AFP sero-survey in diagnosis and screening of hepatocellular carcinoma. Nat. med. J. China 53 (1973) 455–457. (In Chinese)Google Scholar
  17. 17.
    Shanghai Coordinating Group for Research on Liver Cancer: Diagnosis and treatment of primary hepatocellular carcinoma in early stage — report of 134 cases. Chin. med. J. 92 (1979) 801–806Google Scholar
  18. 18.
    Tang ZY: A new concept on the natural course of hepatocellular carcinoma. Chin. med. J. 94 (1981) 585–588PubMedGoogle Scholar
  19. 19.
    Tang ZY (Edit.): Subclinical Hepatocellular Carcinoma. Beijing: China Academic Publ.; Berlin: Springer 1985Google Scholar
  20. 20.
    Tang ZY: Current status of treatment of hepatocellular carcinoma. Chin. med. J. 98 (1985) 257–264PubMedGoogle Scholar
  21. 21.
    Tang ZY: Hepatocellular carcinoma — When should we stop surgery? (Guest editorial). J. exp. clin. Cancer Res. 4 (1985) 5–9Google Scholar
  22. 22.
    Tang ZY, Lu JZ, Zhou NQ et al.: Small hepatocellular carcinoma (HCC). VI. Value of hepatoarteriography, B-scan ultrasonography and liver scintiscan in the localization of small HCC — a comparative study based on operative findings. Acta acad. med. primae Shanghai 9 (1982) 101–105. (In Chinese)Google Scholar
  23. 23.
    Tang ZY, Yang BH: Primary liver cancer — clinical analysis of 3254 cases (from 11 provinces, 21 hospitals, in China). Cancer Res. Prev. Treatm. 2 (1974) 207–215. (In Chinese)Google Scholar
  24. 24.
    Tang ZY, Yang BH: Clinical evaluation of alpha-fetoprotein as tumor marker for hepato-cellular carcinoma. Chin. J. Oncol. 3 (1981) 205–209. (In Chinese)Google Scholar
  25. 25.
    Tang ZY, Yang BH, Tang CL et al.: Evaluation of population screening for hepatocellular carcinoma. Chin. med. J. 93 (1980) 795–799PubMedGoogle Scholar
  26. 26.
    Tang ZY, Ying YY, Gu TJ: Hepatocellular carcinoma — changing concepts in recent years. In H.Popper, F.Schaffner (eds): Progress in Liver Diseases, Vol.7, pp. 637–647. New York: Grune & Stratton 1982Google Scholar
  27. 27.
    Tang ZY, Yu YQ, Zhou XD: An important approach to prolonging survival further after radical resection of AFP positive hepatocellular carcinoma. J. exp. clin. Cancer Res. 3 (1984) 359–368Google Scholar
  28. 28.
    Wen YM, Mitamura K, Merchant B et al.: Nuclear antigen detected in hepatoma cell lines containing integrated hepatitis B virus DNA. Infect. Immun. 39 (1983) 1361–1367PubMedGoogle Scholar
  29. 29.
    World Health Organization: Prevention of Liver Cancer. WHO Techn. Rep. Ser. No.691. Geneva 1983Google Scholar
  30. 30.
    Xu KL, Yu EX, Lu LN et al.: Alpha-fetoprotein variants and their clinical significance. Chin. med. J. 97 (1984) 538–542PubMedGoogle Scholar
  31. 31.
    Xu SK, Guan SF, Wang GL et al.: Assay of alpharantitrypsin activity in the diagnosis of hepatocellular carcinoma — determination of serum trypsin inhibitor capacity. Tumor 1 (1981) 245–248. (In Chinese)Google Scholar
  32. 32.
    Yang BH, Tang ZY: Primary liver cancer–a clinical analysis of 1045 cases. In Z.Y.Tang (Edit.): Primary Liver Cancer, pp. 366–374. Shanghai: Shanghai Sci. Techn. Publ. 1981. (In Chinese)Google Scholar
  33. 33.
    Yang BH, Tang ZY: Evaluation of 5′-nucleotide phosphodiesterase isozyme V for the diagnosis of primary liver cancer. Acta acad. med. primae Shanghai 9 (1982) 275–278. (In Chinese)Google Scholar
  34. 34.
    Ying YY, Zhou WR, Sung QL et al.: The relationship between hepatitis B virus, liver cirrhosis and primary hepatocellular carcinoma. Tumor 1 (1981) 49–53. (In Chinese)Google Scholar
  35. 35.
    Yu SZ: Epidemiology of primary liver cancer. In Z.Y.Tang (Edit.): Subclinical Hepatocellular Carcinoma, pp. 188–211. Beijing: China Academic Publ.; Berlin: Springer 1985Google Scholar
  36. 36.
    Yu YQ, Tang ZY, Zhou XD et al.: Treatment of primary hepatic cancer by YAG laser, a preliminary report. Acta acad. med. primae Shanghai 8 (1981) 29–31. (In Chinese)Google Scholar
  37. 37.
    Zhou XD, Tang ZY, Yu YQ et al.: Cryosurgery for liver cancer — experimental and clinical study. Chin. J. Surg. 17 (1979) 480–483. (In Chinese)PubMedGoogle Scholar
  38. 38.
    Zhu YR, Lu BX: Clinical implication of AFP sero-survey. Chin. J. Oncol. 5 (1983) 38–40. (In Chinese)Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Tang Zhao-You
  • Yu Ye-Qin
  • Yang Bing-Hui

There are no affiliations available

Personalised recommendations